Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Vaccine. 2005 Mar 18;23(17-18):2228-30.

New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery.

Author information

  • 1Institute of Environmental Science and Research (ESR), 34 Kenepuru Drive, Porirua, New Zealand.

Abstract

New Zealand's epidemic of meningococcal disease began in mid 1991. Surveillance of meningococcal disease in New Zealand is based on a combination of disease notification and organism characterisation. Case numbers and population rates rose from 53 (1.5 per 100,000 population) in 1990 to a high of 650 (17.4 per 100,000 population) in 2001. The highest rates of disease occur in Pacific peoples under 20 years but the highest percentages of cases occur in Maori and European New Zealanders. The epidemic has been driven by a strain identified as B:4:P1.7b,4, ST-41/44 complex/Lineage III. The stability of the P1.7b,4 Por A protein has been demonstrated suggesting that the epidemic may be controlled by a strain-specific OMV vaccine.

PMID:
15755601
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk